Osteoporosis: A Long-Term and Late-Effect of Breast Cancer Treatments

被引:38
作者
Shapiro, Charles L. [1 ,2 ]
机构
[1] Icahn Sch Med, Hematol & Med Oncol, 1470 Madison Ave, New York, NY 10029 USA
[2] Tisch Canc Inst Mt Sinai, 1470 Madison Ave, New York, NY 10029 USA
关键词
osteoporosis; bone loss; chemotherapy-induced ovarian failure; aromatase inhibitors; zoledronic acid; denosumab; BONE-MINERAL DENSITY; ADJUVANT ENDOCRINE THERAPY; VITAMIN-D DEFICIENCY; POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; EARLY-STAGE; AROMATASE INHIBITOR; PREMENOPAUSAL WOMEN; FRACTURE RISK; BILATERAL OOPHORECTOMY;
D O I
10.3390/cancers12113094
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Osteoporosis is a prevalent condition affecting 200 million individuals world-wide. Estimates are about one in three women will experience a fragility fracture of hip, spine or wrist. Common breast cancer treatments, such as aromatase inhibitors in postmenopausal women and chemotherapy-induced ovarian failure in premenopausal women, cause bone loss that in some women will lead to osteoporosis and fragility fractures. Fragility fractures cause morbidity and mortality and are entirely preventable. Prevention or treatment of osteoporosis includes lifestyle modifications (e.g., reducing smoking and excessive alcohol consumption, and increasing physical activity), taking calcium and vitamin D3, screening for osteoporosis with dual-energy absorptiometry, and treatment, if clinically indicated, with ether oral bisphosphonates, intravenous zoledronic acid, or subcutaneous denosumab. This chapter reviews the pathogenesis of osteoporosis, the magnitude of bone loss related to common breast cancer treatments, osteoporosis risk factor assessment and screening, and the specific drugs to treat or prevent osteoporosis. Osteoporosis is both a long-term effect (occurs during treatment and extends after treatment) and a late-effect (occurs after treatment ends) of breast cancer treatments. The worldwide prevalence of osteoporosis is estimated to be some 200 million patients. About one in three postmenopausal women will experience an osteoporotic (or fragility) fracture of the hip, spine, or wrist. breast cancer treatments, including gonadotropin-releasing hormone (GnRH) agonists, chemotherapy-induced ovarian failure (CIOF), and aromatase inhibitors (AIs), cause bone loss and increase the risks of osteoporosis. Also, breast cancer is a disease of aging, and most of the "one in eight" lifetime risks of breast cancer are in women in their sixth, seventh, and eighth decades. The majority of women diagnosed with breast cancers today will be long-term survivors and experience personal cures. It is the coalescence of osteoporosis with breast cancer, two common and age-related conditions that make osteoporosis relevant in women with breast cancer throughout the continuum from diagnosis, treatment, and survivorship. It is critical to remember that women (and men) will lose bone after age thirty years. However, only certain women will lose bone of sufficient magnitude to merit treatment with anti-osteoporosis drugs. The narrative review is intended for medical, surgical, radiation oncologists, and other mid-level providers, and provides an overview of bone loss and the prevention and treatment of osteoporosis.
引用
收藏
页码:1 / 17
页数:18
相关论文
共 125 条
[1]   Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial [J].
Aft, Rebecca ;
Naughton, Michael ;
Trinkaus, Kathryn ;
Watson, Mark ;
Ylagan, Lourdes ;
Chavez-MacGregor, Mariana ;
Zhai, Jing ;
Kuo, Socha ;
Shannon, William ;
Diemer, Kathryn ;
Herrmann, Virginia ;
Dietz, Jill ;
Ali, Amjad ;
Ellis, Matthew ;
Weiss, Peter ;
Eberlein, Timothy ;
Ma, Cynthia ;
Fracasso, Paula M. ;
Zoberi, Imran ;
Taylor, Marie ;
Gillanders, William ;
Pluard, Timothy ;
Mortimer, Joanne ;
Weilbaecher, Katherine .
LANCET ONCOLOGY, 2010, 11 (05) :421-428
[2]  
[Anonymous], 2004, BON HLTH OST
[3]   Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis [J].
Artigalas, Osvaldo ;
Vanni, Tazio ;
Hutz, Mara Helena ;
Ashton-Prolla, Patricia ;
Schwartz, Ida Vanessa .
BMC MEDICINE, 2015, 13
[4]   Fragility fracture: recent developments in risk assessment [J].
Aspray, Terry J. .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2015, 7 (01) :17-25
[5]   Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men [J].
Avenell, Alison ;
Mak, Jenson C. S. ;
O'Connell, Dianne .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04)
[6]   St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment [J].
Balic, Marija ;
Thomssen, Christoph ;
Wuerstlein, Rachel ;
Gnant, Michael ;
Harbeck, Nadia .
BREAST CARE, 2019, 14 (02) :103-110
[7]   Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial [J].
Banys, Malgorzata ;
Solomayer, Erich-Franz ;
Gebauer, Gerhard ;
Janni, Wolfgang ;
Krawczyk, Natalia ;
Lueck, Hans-Joachim ;
Becker, Sven ;
Huober, Jens ;
Kraemer, Bernhard ;
Wackwitz, Birgit ;
Hirnle, Peter ;
Wallwiener, Diethelm ;
Fehm, Tanja .
BMC CANCER, 2013, 13
[8]   Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives [J].
Beuzeboc, Philippe ;
Scholl, Suzy .
JOURNAL OF CLINICAL MEDICINE, 2014, 3 (02) :521-536
[9]   Postmenopausal Osteoporosis [J].
Black, Dennis M. ;
Rosen, Clifford J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (03) :254-262
[10]   Calcium intake and risk of fracture: systematic review [J].
Bolland, Mark J. ;
Leung, William ;
Tai, Vicky ;
Bastin, Sonja ;
Gamble, Greg D. ;
Grey, Andrew ;
Reid, Ian R. .
BMJ-BRITISH MEDICAL JOURNAL, 2015, 351